⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEVA News
Teva Pharmaceutical Industries Limited American Depositary Shares
ENT Disorder Treatment Market to Reach US$58 Billion by 2034, Driven by Digital Diagnostics and Minimally Invasive Car
globenewswire.com
GSK
SNY
PFE
AZN
NVS
ABBV
JNJ
MRK
MDT
SN
BSX
TEVA
SUN
Stock Drop Notice: Zillow ($Z, $ZG) 17% Stock Drop Triggers Securities Fraud Class Action Lawsuit - Investors Alerted to August 10 Court Deadline
accessnewswire.com
Z
ZG
TSLA
TEVA
Stock Drop Notice: AeroVironment ($AVAV) 17% Stock Drop Triggers Securities Fraud Class Action Lawsuit - Investors Alerted to July 27 Court Deadline
accessnewswire.com
AVAV
TSLA
TEVA
The 43rd National Pharmaceutical Industry Information Annual Conference and the 2026 Beijing · Changping Life Science Forum Held in Beijing
globenewswire.com
DHR
BIIB
BMY
GILD
MRK
PFE
REGN
SNY
XOM
LLY
ABBV
AMGN
AZN
JNJ
NVS
TEVA
VRTX
NVDA
GOOG
MSFT
As Enterprises Move AI Agents Into Production, OpenBox AI and Temporal Introduce Runtime Governance for Long-Running Agents
prnewswire.com
NFLX
SNOW
CHKP
DDOG
CRM
S
AMZN
GOOG
MSFT
IBM
ORCL
CSCO
INTC
NVDA
AMD
META
ADBE
PYPL
CMCSA
VZ
T
BA
GE
CAT
DIS
MCD
KO
PEP
JNJ
PG
XOM
CVX
WMT
HD
UNH
MA
V
JPM
BAC
WFC
C
GS
MS
AXP
BLK
PRU
MET
AIG
CB
MSCI
SPGI
ICE
NDAQ
AMAT
MU
ASML
KLAC
ADSK
CDNS
MRVL
QCOM
TXN
LRCX
ADI
MCHP
NXPI
ON
ALGN
BIIB
GILD
AMGN
REGN
VRTX
BMY
PFE
MRK
ABBV
LLY
JAZZ
AZN
SNY
NVS
TEVA
ACN
TMO
ISRG
DASH
UBER
LYFT
GOOGL
AAPL
TSLA
GM
F
RIVN
LCID
NIO
XPEV
PLTR
SMCI
CRWD
PANW
SNPS
MDT
EW
ABT
CI
HUM
CNC
ETSY
BKNG
EXPE
MAR
HLT
IHG
WYNN
LVS
MGM
CCL
RCL
NCLH
AAL
UAL
DAL
LUV
ALK
JBLU
$Z, $ZG Stock Drop: Zillow Stock Plummets 17% after Anticompetitive Agreement Revealed - Securities Fraud Class Action is Ongoing
accessnewswire.com
Z
ZG
TSLA
TEVA
AeroVironment (NASDAQ:AVAV) SCAR Contract Cancellation Triggers Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit
globenewswire.com
AVAV
TSLA
TEVA
Teva und Polpharma Biologics geben globale Lizenzvereinbarung für einen Biosimilar-Kandidaten zu Ocrevus® (Ocrelizumab) zur Behandlung von Multipler Sklerose bekannt
businesswire.com
TEVA
Riassunto: Teva e Polpharma Biologics annunciano un accordo di licenza globale relativo a un candidato biosimilare per Ocrevus® (ocrelizumab) nella sclerosi multipla
businesswire.com
TEVA
Resumen: Teva y Polpharma Biologics anuncian un acuerdo de licencia internacional para un candidato a biosimilar de Ocrevus® (ocrelizumab) para la esclerosis múltiple
businesswire.com
TEVA